PRAXIS Resource Repository

Search our extensive library of COPD care and readmissions reduction resources, including best practices, research articles, educational materials and toolkits.

Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD

Resource Type: Research Papers
0 Comments   |   Like 1 Likes

The COPD Biomarkers Qualification Consortium (CBQC) is a partnership between the COPD Foundation, the U.S. Food and Drug Administration (FDA) and the pharmaceutical industry developed in part to demonstrate that individual biomarkers can be used effectively in the drug development process. This paper presents the process and outcomes of a project seeking approval of fibrinogen, a measure of inflammation, as a biomarker for use in clinical COPD trials.

View Resource
Citation: Mannino DM, Tal-Singer R, Lomas DA, et al. Plasma fibrinogen as a biomarker for mortality and hospitalized exacerbations in people with COPD. J COPD F. 2015; 2(1): 23-34.
exacerbations hospitalization

No Comments

You need to login to comment.

Join Us on COPD360social

Sign In to Participate
Or register to become a member